Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, instead of inhibiting or activating single targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 proof-of-concept clinical trials in psoriasis, asthma, and COVID-19. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma.
View Top Employees from Aldeyra TherapeuticsWebsite | https://www.aldeyra.com/ |
Ticker | ALDX |
Revenue | $953000 |
Funding | $12 million |
Employees | 19 (18 on RocketReach) |
Founded | 2004 |
Address | 131 Hartwell Avenue Suite 320, Lexington, Massachusetts 02421, US |
Phone | (781) 761-4904 |
Fax | (339) 674-6495 |
Technologies |
JavaScript,
HTML,
Twitter
+28 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Business Services |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular Aldeyra Therapeutics employee's phone or email?
The Aldeyra Therapeutics annual revenue was $953000 in 2024.
Todd Brady is the CEO of Aldeyra Therapeutics.
18 people are employed at Aldeyra Therapeutics.
Aldeyra Therapeutics is based in Lexington, Massachusetts.
The NAICS codes for Aldeyra Therapeutics are [32, 325, 3254, 32541].
The SIC codes for Aldeyra Therapeutics are [283, 28].